Abstract
Colon-targeted delivery of bioactives has recently gained importance in addressing specific needs in the therapy of colon based diseases. Many approaches have been attempted for the development of colon-specific delivery systems, with not much success in the past. With the advancement in the field of chronobiology, modern drug delivery approaches have elevated to a new concept of chronopharmacology i.e. the ability to deliver the therapeutic agent to a patient in a staggered profile. The increasing research interest surrounding this delivery system has widened the areas of pharmaceutics in particular with many more sub-disciplines expected to coexist in the near future. Chronopharmaceutics based technology has eliminated the drawbacks associated with the conventional colon specific delivery systems. This review on chronopharmaceutics based delivery lays emphasis on the existing technologies and future development.
Keywords: Colon-targeted delivery, chronopharmaceutics, drug delivery systems, modern technology, drug dosage, chronobiology, drug release, ulcerative colitis, Crohn’s disease, colorectal cancer
Current Drug Discovery Technologies
Title:Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Volume: 9 Issue: 4
Author(s): Akanksha Tiwari, Raj Kumar Shukla, Suresh Tiwari and Surti Naazneen
Affiliation:
Keywords: Colon-targeted delivery, chronopharmaceutics, drug delivery systems, modern technology, drug dosage, chronobiology, drug release, ulcerative colitis, Crohn’s disease, colorectal cancer
Abstract: Colon-targeted delivery of bioactives has recently gained importance in addressing specific needs in the therapy of colon based diseases. Many approaches have been attempted for the development of colon-specific delivery systems, with not much success in the past. With the advancement in the field of chronobiology, modern drug delivery approaches have elevated to a new concept of chronopharmacology i.e. the ability to deliver the therapeutic agent to a patient in a staggered profile. The increasing research interest surrounding this delivery system has widened the areas of pharmaceutics in particular with many more sub-disciplines expected to coexist in the near future. Chronopharmaceutics based technology has eliminated the drawbacks associated with the conventional colon specific delivery systems. This review on chronopharmaceutics based delivery lays emphasis on the existing technologies and future development.
Export Options
About this article
Cite this article as:
Tiwari Akanksha, Kumar Shukla Raj, Tiwari Suresh and Naazneen Surti, Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems, Current Drug Discovery Technologies 2012; 9 (4) . https://dx.doi.org/10.2174/157016312803305889
DOI https://dx.doi.org/10.2174/157016312803305889 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phylogenetic Aspects of Nucleobindin-2/Nesfatin-1
Current Pharmaceutical Design Polymorphism of UDP-Glucuronosyltransferase and Drug Metabolism
Current Drug Metabolism Editorial [Hot topic: Transportalopathy and Vascular Cell Dysfunction (Guest Editor: Luis Sobrevia)]
Current Vascular Pharmacology Comparison of Changes in Cognitive Functions of Post-stroke Patients with the Computer-based Cognitive Intervention (PABLO System) and Conventional Cognitive Intervention (Paper-pencil Method)
Current Psychiatry Research and Reviews Efficacy of High-Dose Vitamin D Supplementation in the Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic: Recent Perspectives on Nanoneuroprotection & Nanoneurotoxicity (Guest Editors: Hari Shanker Sharma and Aruna Sharma)]
CNS & Neurological Disorders - Drug Targets Allograft-Induced Proliferation of Vascular Smooth Muscle Cells: Potential Targets for Treating Transplant Vasculopathy
Current Vascular Pharmacology p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Preface (Hot Topic:Cardiovascular and Hematological Disorders Executive Editor: Dr. Johann Auer)
Current Pharmaceutical Design Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviews Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design Cholesterol Ester Transfer Protein (CETP), Postprandial Lipemia and Hypolipidemic Drugs
Current Medicinal Chemistry Current Pharmacological Treatment of Nonalcoholic Fatty Liver
Current Medicinal Chemistry Aqueous Extract of Arbutus unedo Inhibits STAT1 Activation in Human Breast Cancer Cell Line MDA-MB-231 and Human Fibroblasts Through SHP2 Activation
Medicinal Chemistry The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer
Current Angiogenesis (Discontinued) Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology